Kristina Jankovic, Medical Oncology Resident at the University Clinical Center Niš, shared an article by John F.R. Robertso on X:
“Final OS analysis from FALCON:
- No significant difference between fulvestrant (44.8 months) and anastrozole (42.7 months) in ET-naive HR+ ABC.
- 15% risk of death with fulvestrant in nonvisceral disease (65.2 vs. 47.8 months).”
Fulvestrant Versus Anastrozole in Endocrine Therapy–Naïve Women With Hormone Receptor–Positive Advanced Breast Cancer: Final Overall Survival in the Phase III FALCON Trial.
Authors: John F.R. Robertso, et al.
